The new report, published in BMC Pediatrics, describes a retrospective single-center case series of seven children with pediatric acute respiratory distress syndrome, or PARDS, who also had acute kidney injury. In each case, the clinicians integrated extracorporeal carbon dioxide removal, known as ECCO₂R, into a CRRT circuit that had already been indicated for kidney support. Rather than adding a second large-bore extracorporeal circuit dedicated solely to lung support, the team adapted the existing blood purification circuit so that it could also strip carbon dioxide from the bloodstream. The study was retrospectively registered in the German Clinical Trials Register as DRKS00038799.

The physiological logic behind the technique is straightforward but demanding in practice. ECCO₂R works by passing blood through a gas exchanger, essentially an artificial membrane lung, where a controlled flow of oxygen sweeps carbon dioxide across the membrane and out of the blood. The removed CO₂ is then vented away, and the blood returns to the patient with a lower carbon dioxide tension. Because carbon dioxide diffuses through membranes far more readily than oxygen does, meaningful CO₂ clearance can be achieved at blood flows far lower than those required for full extracorporeal membrane oxygenation, or ECMO. In adults, this has made ECCO₂R attractive as a way to permit ultra-lung-protective ventilation, in which tidal volumes and airway pressures are driven down to minimize ventilator-induced lung injury while the artificial circuit takes over the burden of CO₂ elimination.

In children, however, the technique has remained largely unexplored territory. Pediatric patients have smaller blood volumes, lower cardiac outputs, and narrower vascular access, all of which complicate the extracorporeal circuits designed primarily for adults. The Freiburg team’s insight was that children who need both lung support and kidney support could, in principle, have both delivered through a single circuit. CRRT machines already circulate blood continuously through an extracorporeal loop; adding a gas exchanger in that loop converts the circuit into a dual-purpose organ support system without the need for additional large-bore cannulation.

To assess how this played out in practice, the researchers analyzed the first treatment episode for each of seven patients treated between November 2023 and November 2025, restricting the principal analysis to one episode per patient to avoid the statistical problems that arise when repeated observations from the same child are treated as independent. The children had a median age of 12 years, with an interquartile range of 6 to 14 years. ECCO₂R was delivered at a median blood flow of 270 milliliters per minute, with an interquartile range of 100 to 300 milliliters per minute. That flow corresponds to roughly 9 percent of the estimated cardiac output, with an interquartile range of 6 to 20 percent, a strikingly modest fraction compared with the much higher flows typical of ECMO.

The physiological results, analyzed with Friedman tests for longitudinal change, showed statistically significant improvements across all predefined principal outcomes. Median arterial carbon dioxide tension, or PaCO₂, fell by 10 millimeters of mercury within the first 24 hours, with an interquartile range of −27 to −3 millimeters of mercury. Peak inspiratory pressure dropped by a median of 11 millibars, driving pressure by 9 millibars, and tidal volume by 1.6 milliliters per kilogram of body weight. Each of these shifts points in the direction that lung-protective ventilation strategies aim for: less pressure, less stretch, less stress on injured lung tissue, achieved while carbon dioxide was being cleared extracorporeally rather than by aggressive ventilator settings.

On the safety front, the picture was cautiously reassuring but not unblemished. The investigators found no predefined major bleeding events, no clinically apparent hemolysis, no thromboembolic complications, and no device-related infections attributable to the integrated ECCO₂R-CRRT approach. The main complication observed was circuit clotting requiring circuit exchange, which occurred in two of the seven patients. Four of the seven children were successfully weaned from ECCO₂R during their treatment course. For a first-in-children application of an adapted circuit, these figures suggest that the approach can be delivered without an outsized burden of extracorporeal complications, though the small sample size and retrospective design make it impossible to draw firm conclusions about true event rates.

The authors are careful to frame their findings as hypothesis-generating rather than as evidence of treatment efficacy or device safety. This is a retrospective, uncontrolled, single-center case series with seven patients in the principal analysis, and the observed improvements in PaCO₂ and ventilatory pressures are temporally associated with ECCO₂R initiation rather than causally attributable to it. Children with PARDS and AKI are a heterogeneous group, and natural disease evolution, changes in sedation, adjustments in ventilator strategy, and concurrent therapies could all contribute to the measured changes. Still, the consistency of the physiological signal across multiple outcomes, and the fact that it emerged in a real-world pediatric intensive care setting rather than a highly controlled research protocol, gives the findings practical weight.

The study also highlights the interdisciplinary machinery required to make such an approach work. The authors specifically acknowledge the dialysis nursing team, the Division of Pediatric Nephrology, and the nursing staff of the Pediatric Intensive Care Unit at the Medical Center – University of Freiburg, noting that their expertise and dedication were essential to successful implementation. They also thank the family of the first child treated with integrated ECCO₂R-CRRT at the institution for supporting publication of the experience. The research received no dedicated financial support, with open access funding organized through Projekt DEAL, and the authors declare no competing interests.

Looking ahead, the Freiburg team argues that prospective multicenter studies are needed to define patient selection criteria, anticoagulation strategies, weaning protocols, and the broader role of integrated ECCO₂R-CRRT within pediatric extracorporeal respiratory support. If those questions can be answered, the approach could offer a pragmatic middle ground for carefully selected children who need both kidney and lung support, avoiding the cannulation burden and complexity of full ECMO while still relieving the ventilator of some of its most dangerous demands. For now, the message is one of cautious optimism: a technique borrowed from adult critical care, adapted to the constraints of pediatric physiology and existing dialysis infrastructure, appears technically feasible and physiologically promising in a small, carefully selected cohort.

Subject of Research: Extracorporeal carbon dioxide removal integrated into continuous renal replacement therapy for pediatric acute respiratory distress syndrome

Article Title: Extracorporeal carbon dioxide removal integrated into continuous renal replacement therapy in pediatric patients with ARDS: a retrospective single-center case series

Article References: Kuntz, M., Matheisl, D., Schüle, I., Klotz, D., Fuchs, H., & Schneider, H. (2026). Extracorporeal carbon dioxide removal integrated into continuous renal replacement therapy in pediatric patients with ARDS: a retrospective single-center case series. BMC Pediatrics, 26(1), Article 860. https://doi.org/10.1186/s12887-026-07656-y

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07656-y

Keywords: ECCO2R, continuous renal replacement therapy, pediatric ARDS, acute kidney injury, lung-protective ventilation, pediatric critical care, extracorporeal membrane oxygenation, carbon dioxide removal, case series, pediatric intensive care, ventilator pressures, BMC Pediatrics

The research, conducted at Lapeyronie University Hospital in Montpellier and published in the Journal of Artificial Organs, analyzed 17 patients treated with high-flow ECCO2R between January 2018 and May 2024. All patients received extracorporeal blood flows of at least 2 liters per minute, delivered through an ECMO console with a large membrane oxygenator and two single-lumen cannulas inserted on the same side of the body. Because the drainage and reinfusion cannulas are separate, the team could deliberately vary the position of the draining cannula, creating four distinct configurations: central and distal versions of both a jugular-jugular and a femoro-femoral setup. In the central configurations, the multistage draining cannula was advanced through the right atrium, while in the distal configurations it remained close to the reinfusion cannula in the distal portions of the vena cava.

The physiological variable at the heart of the study is recirculation, a phenomenon familiar to anyone who works with extracorporeal circuits. When freshly reinfused blood is immediately sucked back into the draining cannula, the machine processes the same blood twice while the patient’s CO2-rich venous return flows past untouched. The team quantified this with a recirculation coefficient calculated from oxygen saturations in the inlet and outlet lines of the oxygenator, using an assumed mixed venous saturation of 65 percent, and validated the approach with sensitivity analyses across a range of plausible values. They also computed the effective extracorporeal blood flow, the portion of the pump flow that actually represents new blood from the patient, and measured CO2 elimination across the membrane in standard-temperature-and-pressure-dried milliliters per minute.

The results were stark. In the central drainage configurations, the median recirculation coefficient was just 9 percent, whereas the distal configurations produced a median of 59 percent, more than six times higher. Effective blood flow collapsed accordingly: about 2.1 liters per minute in the central setups versus 0.9 liters per minute in the distal ones, with the distal femoro-femoral configuration falling to a median of only 0.5 liters per minute. Because CO2 transfer depends on both how much blood crosses the membrane and how much CO2 that blood carries, this hidden shunting translated directly into lost decarboxylation. Median CO2 elimination was 122 milliliters per minute with central drainage but only 58 milliliters per minute with distal drainage, despite comparable nominal pump flows between the groups.

The statistical analysis went beyond simple comparison. Using multivariable linear mixed models that accounted for repeated measurements in each patient, the researchers examined how much CO2 elimination increased for each unit of the decarboxylation index, a product of blood flow and sweep gas flow that they had previously validated as a predictor of performance. For every additional unit of that index, CO2 elimination rose 5.2 times less under a distal drainage configuration than under a central one. Compared with the central jugular-jugular reference, the distal jugular-jugular setup lost 3.2 milliliters per minute of CO2 elimination per unit of index, and the distal femoro-femoral setup lost 5.2 milliliters per minute, both highly significant. The central femoro-femoral configuration performed nearly as well as the jugular reference, a difference that was not statistically significant.

The mechanics behind this failure of distal drainage are rooted in fluid dynamics and venous anatomy. In the distal portions of the superior or inferior vena cava, the available blood volume is small, the side holes of the cannula can be occluded by the venous wall, and the negative pressures generated by spontaneous breathing further reduce the suction gradient. As a result, the proportion of drainage drawn from freshly reinfused blood rapidly becomes dominant, and recirculation soars. High recirculation also lowers the CO2 content of the blood entering the oxygenator, and because diffusion across the membrane follows Fick’s law, a lower inlet CO2 concentration means less driving force for transfer. The machine appears to be working hard while accomplishing progressively less.

These findings carry an uncomfortable implication for standard practice. The authors note that their distal drainage configurations behave much like the single dual-lumen cannulas used in most ECCO2R programs worldwide, in which drainage and reinfusion ports coexist within one catheter. If distal drainage inherently produces high recirculation, the modest decarboxylation performance that has dogged dual-lumen ECCO2R may be a structural feature rather than a fixable flaw. Recent trials have suggested that only veno-venous systems running high blood flows, generally above 2 liters per minute, can meaningfully manage severe respiratory acidosis or reduce ventilator settings, and this study shows that even a nominally high-flow circuit can be quietly sabotaged by cannula geometry. No CO2 elimination value in the distal group reached 110 milliliters per minute.

The study also offers practical guidance for clinicians. The central jugular-jugular configuration, which routes drainage from the inferior vena cava through the right atrium, delivered the best rheological conditions but requires sedation, ultrasound guidance to advance the cannula across the atrium, and head positioning that is uncomfortable for awake patients. The central femoro-femoral configuration emerged as a compelling compromise, providing high and stable flows with acceptable recirculation even in seated, spontaneously breathing patients, thanks to wire-reinforced cannulas and proximal placement near the right atrium. The authors suggest it is particularly suited to awake patients undergoing respiratory weaning with non-invasive ventilation. A further advantage of the two-cannula approach is upgradeability: in case of refractory hypoxemia, the same access sites can be reconfigured into full veno-venous ECMO without new punctures.

Safety data temper the enthusiasm. Nine of the 17 patients, 53 percent, developed one or more thromboembolic events, all of them cannula-associated deep vein thromboses that occurred exclusively in the central drainage group and were detected by systematic CT scanning after decannulation. The authors suspect their anticoagulation targets were too lenient, particularly during the decannulation phase, when endothelial injury from catheter removal activates the coagulation cascade, and they point to percutaneous closure devices as a possible mitigation. The study has other limitations that the authors acknowledge candidly: it is a single-center retrospective analysis with a small and imbalanced cohort, only the first 72 hours of therapy were analyzed to avoid membrane fouling effects, and the recirculation calculation necessarily relies on an assumed mixed venous saturation. Clinical outcomes such as ventilation duration were not assessed. Still, the internal consistency of the findings, replicated across sensitivity analyses and mixed models, makes the central message hard to dismiss. In extracorporeal CO2 removal, the dose delivered to the patient is not set by the pump alone; it is set by the plumbing, and a cannula placed a few centimeters too distal can halve the therapy before it begins.

Subject of Research: Effect of draining cannula position on recirculation and CO2 elimination in high-flow extracorporeal carbon dioxide removal

Article Title: Impact of draining cannula position and configuration under high-flow extracorporeal CO2 removal (ECCO2R) on recirculation and extracorporeal decarboxylation

Article References: Charbit, J., Muller, C., Girard, M., Courvalin, E., Dagod, G., Bouchdoug, K., Deras, P., Weber, H., & Capdevila, X. (2026). Impact of draining cannula position and configuration under high-flow extracorporeal CO2 removal (ECCO2R) on recirculation and extracorporeal decarboxylation. Journal of Artificial Organs, 29(4), Article 69. https://doi.org/10.1007/s10047-026-01582-7

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01582-7

Keywords: ECCO2R, extracorporeal CO2 removal, recirculation, cannula position, ECMO, decarboxylation, respiratory failure, ARDS, COPD, membrane oxygenator, veno-venous support, intensive care

ARDS entered medical history in 1967, when Ashbaugh and colleagues described adults with severe hypoxemia, diffuse pulmonary infiltrates, reduced lung compliance and a clinical picture resembling the “shock lung” previously recognized after trauma. The syndrome is now understood as a form of acute inflammatory lung injury in which the alveolar-capillary barrier becomes abnormally permeable. Fluid floods the air spaces, surfactant function deteriorates, areas of lung collapse, and blood continues to pass through poorly ventilated regions. The result is profound impairment of oxygen transfer. Mechanical ventilation can sustain gas exchange, but excessive pressures and volumes may stretch vulnerable lung tissue, producing ventilator-induced lung injury. Extracorporeal support emerged as a way to interrupt that cycle by transferring part of the work of gas exchange from the damaged lungs to an external circuit.

The earliest systems were technically demanding and associated with substantial complications. In the 1970s, investigators used membrane lungs to oxygenate blood outside the body for patients with severe post-traumatic respiratory failure. A landmark randomized study published in 1979, however, failed to demonstrate a clear survival advantage for extracorporeal membrane oxygenation in severe adult respiratory failure. At the time, equipment limitations, high anticoagulation requirements and inadequate ventilation strategies constrained the therapy. ECMO subsequently declined in adult practice for several decades, even as it became an important treatment for selected newborns and children. The field began to change when improved pumps, polymethylpentene oxygenators, safer vascular cannulation and more protective ventilator strategies made prolonged support more feasible.

The modern revival of adult ECMO was strongly influenced by the CESAR trial, published in 2009, which compared conventional treatment with referral to an ECMO-capable specialist center. The study showed a higher probability of survival without severe disability among patients managed through the specialist pathway, although the trial evaluated referral to a comprehensive center rather than ECMO alone. The 2009 H1N1 influenza pandemic then provided an unexpected global test of the technology. Hospitals in Australia, the United Kingdom, Italy and elsewhere reported that selected patients with otherwise fatal viral pneumonia could survive with ECMO. During the COVID-19 pandemic, international registry studies further demonstrated that VV-ECMO could support patients with severe viral ARDS, although outcomes worsened when systems became overwhelmed and patients were referred after prolonged mechanical ventilation or extensive secondary organ injury.

Venovenous ECMO is designed primarily for respiratory failure. Blood is drained from the venous circulation, propelled through an artificial lung where carbon dioxide diffuses out and oxygen enters, and returned to the right side of the heart. The patient’s own heart then circulates the oxygenated blood through the body. Unlike venoarterial ECMO, which can provide both cardiac and respiratory support, VV-ECMO does not directly replace the pumping function of the heart. Its principal value in ARDS is that it can maintain oxygen delivery while allowing clinicians to reduce ventilator intensity. Lower tidal volumes, lower driving pressures and reduced respiratory rates can limit mechanical stress on the remaining functional lung. In some patients, ECMO also permits prone positioning, spontaneous breathing strategies or carefully controlled near-apneic ventilation, although each approach requires specialized monitoring.

The review emphasizes that ECMO is not a universal treatment for every patient with hypoxemia. Candidates generally have severe, potentially reversible respiratory failure despite optimized conventional care, including lung-protective ventilation, prone positioning and appropriate treatment of the underlying cause. Clinicians must also consider the duration of mechanical ventilation, age, frailty, neurological status and the presence of irreversible disease affecting other organs. Registry analyses and prognostic models such as RESP, PRESERVE and ECMOnet can help structure assessment, but they cannot determine an individual patient’s outcome with certainty. Obesity alone should not automatically exclude a patient, and selected people with cancer or other complex conditions may benefit. Conversely, advanced multisystem organ failure, devastating brain injury or an inability to recover from the underlying disease may make ECMO medically inappropriate.

Once support begins, management extends far beyond the circuit itself. Ventilator settings must be adjusted to avoid continuing injury while ensuring sufficient gas exchange and preventing dangerous derecruitment. Blood flow, sweep gas, oxygen transfer, carbon dioxide removal and recirculation must be assessed together rather than treated as isolated variables. Anticoagulation is usually required because blood contacts artificial surfaces, yet anticoagulation increases the risk of bleeding. Large international studies have documented frequent hemorrhagic and thrombotic events, including cannula-site bleeding, gastrointestinal hemorrhage, intracranial bleeding, oxygenator clotting and circuit thrombosis. Neurological complications are particularly serious; rapid changes in carbon dioxide after ECMO initiation may alter cerebral blood flow and have been associated with brain injury. Infection, limb ischemia, hemolysis, kidney failure, pressure injuries and profound muscle weakness add to the burden of prolonged support.

Liberation from ECMO is another area in which practice is evolving. As the lungs recover, clinicians gradually reduce sweep gas and test whether the patient can maintain acceptable oxygenation and carbon dioxide levels with less extracorporeal assistance. Successful weaning depends on improving pulmonary compliance, gas exchange, respiratory muscle function and the condition of other organs. There is no single universally accepted weaning protocol, and an international survey published in 2026 highlighted continued variation between centers. The review also notes that prone positioning during VV-ECMO remains an active subject of research. The PRONECMO randomized trial found that prone positioning could be performed safely in experienced centers, but broader questions remain about which patients benefit most and whether the strategy improves survival rather than simply oxygenation.

ECCO₂R represents a different concept. Instead of providing enough blood flow to replace most pulmonary gas exchange, ECCO₂R uses a lower-flow extracorporeal circuit primarily to remove carbon dioxide. Because carbon dioxide is more easily removed than oxygen is added, the technology can operate through smaller vascular catheters and may be less invasive than full ECMO. The proposed benefit is “ultra-lung-protective” ventilation: clinicians could reduce tidal volume or airway pressure beyond conventional protective targets while using the circuit to prevent carbon dioxide accumulation. Early studies, including Xtravent and SUPERNOVA, demonstrated technical feasibility and the ability to lower ventilator intensity in selected patients. Yet physiological improvement has not consistently translated into better outcomes. In the REST randomized trial, ECCO₂R-facilitated lower tidal-volume ventilation did not reduce 90-day mortality in patients with acute hypoxemic respiratory failure, and bleeding and other device-related risks remained important concerns.

The future of extracorporeal lung support will therefore depend less on simply building more powerful machines than on identifying the right patient at the right moment. Newer ECCO₂R platforms are being evaluated in mild-to-moderate ARDS, while studies are exploring support before invasive mechanical ventilation, advanced imaging, biological phenotyping and artificial-intelligence-assisted prediction. Researchers are also examining right-ventricular injury, a complication of severe pulmonary vascular stress that may improve when VV-ECMO reduces hypoxemia and unloads the heart. At the same time, long-term follow-up is revealing that survival is only the beginning of recovery. Survivors may experience persistent weakness, impaired cognition, post-traumatic stress, depression, anxiety and new mental-health diagnoses. The central lesson of six decades is therefore both promising and cautionary: ECMO can create time for injured lungs to heal, but it cannot replace careful critical care, and its success must ultimately be measured by meaningful recovery after the circuit is removed.

Subject of Research: Extracorporeal lung support for acute respiratory distress syndrome, including venovenous ECMO and ECCO₂R

Article Title: 60 years of ARDS and the evolution of extracorporeal lung support – from ECMO to ECCO₂R

Article References: Fernando SM, Brodie D, Slutsky AS, et al. “60 years of ARDS and the evolution of extracorporeal lung support – from ECMO to ECCO₂R.” Intensive Care Medicine (2026).

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08533-z

Keywords: Acute respiratory distress syndrome; extracorporeal life support; venovenous ECMO; extracorporeal membrane oxygenation; ECCO₂R; respiratory failure; lung-protective ventilation